JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nuwayhid, S. J.
Right arrow Articles by Werling, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nuwayhid, S. J.
Right arrow Articles by Werling, L. L.

Vol. 304, Issue 1, 364-369, January 2003

sigma 1 Receptor Agonist-Mediated Regulation of N-Methyl-D-aspartate-Stimulated [3H]Dopamine Release Is Dependent upon Protein Kinase C

Samer J. Nuwayhid and Linda L. Werling

Department of Pharmacology, The George Washington University Medical Center, Washington, DC

We have previously shown that sigma 1 receptor agonists inhibit N-methyl-D-aspartate (NMDA)-stimulated [3H]dopamine from slices of rat striatum in a concentration-related manner and that the inhibition is reversed by sigma 1 receptor-selective and nonsubtype-selective sigma  receptor antagonists. Based on previous evidence from our laboratory as well as other laboratories, we hypothesized that sigma 1 receptors might use a protein kinase C (PKC) signaling pathway to modulate stimulated dopamine release. We tested several inhibitors of PKC isozymes, as well as a phospholipase C inhibitor for their effects on sigma 1 receptor agonist-mediated regulation of [3H]dopamine release. Although none of the inhibitors tested affected the ability of NMDA to stimulate [3H]dopamine release, they all abolished regulation by the sigma 1 receptor agonist (+)-pentazocine in a concentration-related manner. We also found that prior exposure to 1 µM phorbol 2-myristate 13-acetate for 30 min abolished regulation by (+)-pentazocine. We concluded that an intact PKC system was required for sigma 1 agonist-mediated regulation of NMDA-stimulated [3H]dopamine release from rat striatal slices. Based on the pharmacological profile of the PKC inhibitors tested, as well as reports in the literature on PKC involvement in neurotransmitter release and sigma  receptor action, PKCbeta seems most likely to be responsible, at least in part, for the effects of (+)-pentazocine on dopamine release.

0022-3565/03/3041-0364$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 IOVSHome page
K. T. Tchedre, R.-Q. Huang, A. Dibas, R. R. Krishnamoorthy, G. H. Dillon, and T. Yorio
Sigma-1 Receptor Regulation of Voltage-Gated Calcium Channels Involves a Direct Interaction
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4993 - 5002.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Liu and R. R. Matsumoto
Alterations in Fos-Related Antigen 2 and {sigma}1 Receptor Gene and Protein Expression Are Associated with the Development of Cocaine-Induced Behavioral Sensitization: Time Course and Regional Distribution Studies
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 187 - 195.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Dun, M. Thangaraju, P. Prasad, V. Ganapathy, and S. B. Smith
Prevention of Excitotoxicity in Primary Retinal Ganglion Cells by (+)-Pentazocine, a Sigma Receptor-1 Specific Ligand
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4785 - 4794.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Cormaci, T. Mori, T. Hayashi, and T.-P. Su
Protein Kinase A Activation Down-Regulates, Whereas Extracellular Signal-Regulated Kinase Activation Up-Regulates {sigma}-1 Receptors in B-104 Cells: Implication for Neuroplasticity
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 202 - 210.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Liu, G.-D. Chen, M. R. Lerner, D. J. Brackett, and R. R. Matsumoto
Cocaine Up-Regulates Fra-2 and {sigma}-1 Receptor Gene and Protein Expression in Brain Regions Involved in Addiction and Reward
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 770 - 779.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Kurata, M. Takebayashi, S. Morinobu, and S. Yamawaki
{beta}-Estradiol, Dehydroepiandrosterone, and Dehydroepiandrosterone Sulfate Protect against N-Methyl-D-aspartate-Induced Neurotoxicity in Rat Hippocampal Neurons by Different Mechanisms
J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 237 - 245.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. J. Nuwayhid and L. L. Werling
Steroids Modulate N-Methyl-D-aspartate-Stimulated [3H]Dopamine Release from Rat Striatum via {sigma} Receptors
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 934 - 940.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Hayashi and T.-P. Su
{sigma}-1 Receptors ({sigma}1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 718 - 725.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Hayashi and T.-P. Su
Intracellular Dynamics of {sigma}-1 Receptors ({sigma}1 Binding Sites) in NG108-15 Cells
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 726 - 733.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.